Zusammenfassung
Zur Beurteilung neuer Konzepte in der Langzeitbehandlung schizophrener Patienten wurden drei neuere kontrollierte, prospektive Studien skizziert und in ihren Hauptzielkriterien einander gegenübergestellt. Dabei handelt es sich um die Untersuchungen von Carpenter et al. [3], Jolley et al. [14] und der ANI-Studiengruppe [22]. Im Vordergrund stand bei allen Studien die Absicht, die Risiken einer neuroleptischen Dauergabe zu vermeiden bzw. zu reduzieren. So wurde eine kontinuierliche Langzeitmedikation mit einer intermittierenden, symptomorientierten Gabe von Neuroleptika verglichen. In allen drei Studien ist die Drop-out- und Rezidivrate bei den symptomorientierten Behandlungsstrategien signifikant höher als bei der neuroleptischen Dauergabe. Die Neuroleptikadosis der symptomorientierten Behandlung war bei den Untersuchungen der Arbeitsgruppen von Carpenter und Jolley signifikant niedriger als die der Langzeitmedikation. Die entsprechenden Ergebnisse der ANI-Studiengruppe werden derzeit publiziert.
Summary
New concepts for the relapse prophylactic treatment of schizophrenic patients. In order to assess new concepts in the long-term treatment of schizophrenic patients, three controlled prospective studies were recently drafted and their main target-related criteria compared with one another.
These were the studies by Carpenter et al. [3] and Jolley et al. [14] as well as the German ANI study group [22]. In all studies the foremost intention was to avoid or to minimize the risk of a continuous neuroleptic treatment. Thus, an uninterrupted long-term medication was compared with an intermittent targeted administration of neuroleptics. In each study the drop-out and relapse rate of the targeted application of neuroleptics was significantly higher than in the neuroleptic long-term administration. The neuroleptic dose of the targeted medication in the studies by Carpenter et al. and Jolley et al. was significantly lower than in the long-term medication. The corresponding results of the ANI study group will soon be published.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Baldessarini RJ, Davis JM (1980) What ist the best maintenance dose of neuroleptics in schizophrenia? Psychiatr Res 3: 115–122
Bleuler M (1968) A 23-year longitudinal study of 208 schizophrenics and impressions in regard to nature of schizophrenia. In: Rosenthal D, Kety SS (eds) The transmission of schizophrenia. Pergamon Press, Oxford C. Botschev et al.
Carpenter WT, Hanion TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW (1990) Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147: 1138–1148
Cheung HK (1981) Schizophrenics fully remitted on neuroleptics for 3–5 years: to stop or to continue drugs? Br J Psychiatry 138: 490–494
Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics. Am J Psychiatry 137: 16–20
Ciompi L, Müller C (1976) Lebensweg und Alter der Schizophrenien. Eine katamnestische Langzeitstudie bis ins Senium. Springer, Berlin Heidelberg New York
Crow IJ, McMillan JF, Johnson AL, Johnstone EC (1986) II. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148: 120–127
Gaebel W, Kopeke W, Linden M, Müller P, Müller-Spahn F, Pietzcker A, Tegeler J (1991) Two year outcome of intermittent vs maintenance neuroleptic treatment in schizophrenia. Vortrag, International Congress on Schizophrenia Research, Tucson, Arizona, 21–25. 4. 1991
Häfner H (1988) Epidemiologie der Schizophrenie. Stand und Per-spektiven. Fundamenta Psychiatrica 4: 264–282
Herz MI, Syzmanski HV, Simon JC (1982) Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry 139: 918–922
Huber G, Gross G, Schüttler R (1979) Schizophrenie. Eine Verlaufs- und sozialpsychiatrische Langzeitstudie. Springer, Berlin Heidelberg New York
Jain AK, Kelwala S, Gershon S (1988) Antipsychotic drugs in schizophrenia: currrent issues. Int Clin Psychopharmacol 3: 1–30
Johnson DAW, Ludlow JM, Street K, Taylor RDW (1987) Double- blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry 151: 634–638
Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. Br Med J 301: 837–842
Kane JM, Rifkin A, Quitkin F, Naya D, Ramos-Lorenzi J (1982) Fluphenazine versus placebo in patients with remitted acute first schizophrenia. Arch Gen Psychiatry 39: 70–73
Kane JM, Rifkin A, Woerner M, Reardon G, Sarantokos S, Schiebel D, Ramos-Lorenzi J (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry 40: 893–896
Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, Borenstein M (1985) High-dose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacol Bull 21: 533–537
Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA (1987) Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 44: 518–521
McGlashan TH (1988) A selective review of recent north american long- term followup studies of schizophrenia. Schizophr Bull 14: 515–542
Müller-Spahn F (1990) Neue Aspekte in der Langzeitbehandlung schizophrener Patienten mit Neuroleptica. In: Herz A, Hippius H, Spann W (Hrsg) Psychopharmaka heute. Springer, Berlin Heidelberg New York Tokyo
Overall JE, Gorham DR (1976) Brief Psychiatric Rating Scale. In: Guy W (ed) ECDEU. Assessment manual for psychopharmacology. Rockville, Maryland
Pietzcker A, Gaebel W, Kopeke W, Linden M, Müller P, Müller-Spahn F (1986) A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report. Pharmacopsychiatry 19: 161–166
Pietzcker A (1987) Optimierung der ambulanten neuroleptischen Be-handlung schizophrener Patienten. Überprüfung von Prognosekriterien und Entwicklung von Kriterien zur differentiellen Indikation für verschiedene Behandlungsstrategien. In: Heimann H, Zimmer FT (Hrsg) Chronisch psychisch Kranke. Fischer, Stuttgart New York
Rey MJ, Schulz P, Costa C, Dick P, Tissot R (1989) Guidelines for the dosage of neuroleptics. I. Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Pharmacol 4: 95–104
Watt DC, Katz K, Shepherd M (1983) The natural history of schizo-phrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardizied clinical and social assess¬ment. Psychol Med 13: 663–670
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag/Wien
About this paper
Cite this paper
Botschev, C., Müller-Spahn, F., Kurtz, G. (1992). Neue Therapiekonzepte in der Rezidivprophylaxe schizophrener Patienten. In: König, P. (eds) Rückfallprophylaxe schizophrener Erkrankungen. Aktuelle Probleme der Schizophrenie, vol 3. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9218-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9218-4_2
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82360-6
Online ISBN: 978-3-7091-9218-4
eBook Packages: Springer Book Archive